ACA、ARA和IgG N-糖基化物与糖尿病视网膜病的关系

doi:10.3760/cma.j.cn441417-20240724-16017

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (16): 2725-2728.DOI: 10.3760/cma.j.cn441417-20240724-16017

ACA、ARA和IgG N-糖基化物与糖尿病视网膜病的关系

胡亚红¹ 袁烨² 李军琪³ 张宁¹

¹西安交通大学第一附属医院（东院区）检验科，西安 710089；²西安交通大学第一附属医院（东院区）眼科，西安 710089；³陕西省中西医结合医院（西安市第五医院）眼科，西安 710082

收稿日期:2024-07-24 出版日期:2025-08-15 发布日期:2025-08-28
通讯作者: 李军琪，Email：1930575588@qq.com
基金资助:
陕西省重点研发计划（2021SF-343）

Relationships of ACA, ARA, and IgG N-glycosylates with diabetic retinopathy

Hu Yahong¹, Yuan Ye², Li Junqi³, Zhang Ning¹

¹Department of Clinical Laboratory, East Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710089, China; ²Department of Ophthalmology, East Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710089, China; ³Department of Ophthalmology, Shaanxi Integrated Traditional Chinese and Western Medicine Hospital (Xi'an Fifth Hospital), Xi'an 710082, China

Received:2024-07-24 Online:2025-08-15 Published:2025-08-28
Contact: Li Junqi, Email: 1930575588@qq.com
Supported by:
Key Plan of Research and Development in Shaanxi (2021SF-343)

摘要/Abstract

摘要：

目的　探讨抗心磷脂抗体（ACA）、抗视网膜抗体（ARA）和免疫球蛋白Ｇ（IgG）N-糖基化物与糖尿病视网膜病变（DR）患者病情发生发展的关系。方法　选取2018年6月至2019年6月西安交通大学第一附属医院收治的DR患者75例，并将其分为2组：Ⅰ组为增殖性DR患者35例，Ⅱ组为非增殖性DR患者40例。另选取同期收治的不伴DR的糖尿病患者40例为对照组（Ⅲ组），以及同期在西安交通大学第一附属医院体检的40例健康者为健康组（Ⅳ组）。采用方差分析和χ²检验对比4组受试者的一般资料、生化指标及ACA、ARA和IgG N-糖基化物，并采用二分类logistic回归模型探索IgG N-糖基化物（IGPs）与DR进程的关系。结果　4组收缩压、糖化血红蛋白（HbA1c）、空腹血糖（FBG）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）比较，差异均有统计学意义（均P<0.05）。随DR病情进展，ACA水平和ARA阳性率升高。logistic回归模型发现，IGP31（OR=0.978）、IGP35（OR=0.803）、IGP36（OR=0.784）、IGP37（OR=0.915）和IGP38（OR=0.987）与DR的疾病进展负相关，IGP24（OR=1.039）、IGP28（OR=1.088）、IGP29（OR=1.025）、IGP32（OR=1.038）、IGP34（OR=1.108）与DR疾病进展正相关。结论　ACA、ARA和IgG N-糖基化物与视网膜病变的严重程度密切相关，可以作为预测DR的重要指标。

关键词:

糖尿病视网膜病变, 抗心磷脂抗体, 抗视网膜抗体, 免疫球蛋白Ｇ , N-糖基化物

Abstract:

Objective　To explore the relationships of anticardiolipin antibody (ACA), anti-retinal antibody (ARA), and immunoglobulin G (IgG) N-glycosylates with the conditions and development in patients with diabetic retinopathy (DR). Methods　Seventy-five patients with DR treated at the First Affiliated Hospital of Xi'an Jiaotong University from June 2018 to June 2019 were enrolled, including 35 patients with proliferative DR (group Ⅰ) and 40 patients with non-proliferative DR (group Ⅱ). Forty patients with diabetes mellitus and no retinopathy during the same period were selected as a control group (group Ⅲ). Forty healthy subjects taking physical examination at the First Affiliated Hospital of Xi'an Jiaotong University during the same period were selected as a healthy group (group Ⅳ). Analysis of variance and χ² test were used to compare the general data, biochemical parameters, ACA, ARA, and IgG N-glycosylates between the 4 groups. Binary logistic regression models were used to explore the relationship between IgG N-glycosylates (IGPs) and DR progression. Results　There were statistical differences in the systolic blood pressure, HbA1c, fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) between the 4 groups (all P<0.05). The ACA level and ARA positive rate increased with the progress of DR. The logistic regression model found that IGP31 (OR=0.978), IGP35 (OR=0.803), IGP36 (OR=0.784), IGP37 (OR=0.915), and IGP38 (OR=0.987) were negatively associated with the disease progression of DR, and IGP24 (OR=1.039), IGP28 (OR=1.088), IGP29 (OR=1.025), IGP32 (OR=1.038), and IGP34 (OR=1.108) were positively associated with the disease progression of DR. Conclusion　ACA, ARA, and IgG N-glycosylates are closely related to the severity of retinopathy, and can be used as important predictors of DR.

Key words:

Diabetic retinopathy, Anticardiolipin antibody, Anti-retinal antibody, Immunoglobulin G N-glycosylates

胡亚红袁烨李军琪张宁.

ACA、ARA和IgG N-糖基化物与糖尿病视网膜病的关系 [J]. 国际医药卫生导报, 2025, 31(16): 2725-2728.

Hu Yahong, Yuan Ye, Li Junqi, Zhang Ning.

Relationships of ACA, ARA, and IgG N-glycosylates with diabetic retinopathy [J]. International Medicine and Health Guidance News, 2025, 31(16): 2725-2728.

参考文献

[1] Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and management[J]. Nurs Stand, 2022, 37(1):61-66. DOI:10.7748/ns.2021.e11709.
[2] Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030[J]. Front Endocrinol (Lausanne), 2023, 13:1077669. DOI:10.3389/fendo.2022.1077669.
[3] Cheyne CP, Burgess PI, Broadbent DM, et al. Incidence of sight-threatening diabetic retinopathy in an established urban screening programme: an 11-year cohort study[J]. Diabet Med, 2021, 38(9):e14583. DOI:10.1111/dme.14583.
[4] Li H, Liu X, Zhong H, et al. Research progress on the pathogenesis of diabetic retinopathy[J]. BMC Ophthalmol. 2023, 23(1):372. DOI:10.1186/s12886-023-03118-6.
[5] 中华医学会糖尿病学分会视网膜病变学组. 糖尿病视网膜病变防治专家共识[J]. 中华糖尿病杂志,2018,10(4):241-247. DOI:10.3760/cma.j.issn.1674-5809.2018.04.001.
[6] 中华医学会糖尿病学分会,中国医师协会内分泌代谢科医师分会,中华医学会内分泌学分会,等. 中国1型糖尿病诊治指南(2021版)[J]. 中华糖尿病杂志,2022,14(11):1143-1250. DOI:10.3760/cma.j.cn115791-20220916-00474.
[7] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409. DOI:10.3760/cma.j.cn115791-20210221-00095.
[8] Chong DD, Das N, Singh RP. Diabetic retinopathy: screening, prevention, and treatment[J]. Cleve Clin J Med, 2024, 91(8):503-510. DOI:10.3949/ccjm.91a.24028.
[9] Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK consensus working group[J]. Eye (Lond), 2020, 34 Suppl 1:1-51. DOI:10.1038/s41433-020-0961-6.
[10] Shahin M, El-Diasty AM, Mabed M. Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor[J]. Saudi J Ophthalmol, 2009, 23(2):165-169. DOI:10.1016/j.sjopt.2009.06.001.
[11] 张艺馨,蔡善君,李智立,等. IgGN-糖基化修饰在糖尿病视网膜病变中作用的研究进展[J]. 基础医学与临床,2023,43(3):509-513. DOI:10.16352/j.issn.1001-6325.2023.03.509.
[12] Wu Z, Pan H, Liu D, et al. Variation of IgG N-linked glycosylation profile in diabetic retinopathy[J]. J Diabetes, 2021, 13(8):672-680. DOI:10.1111/1753-0407.13160.
[13] Mandel-Brehm C, Fichtner ML, Jiang R, et al. Elevated N-Linked glycosylation of IgG V regions in myasthenia gravis disease subtypes[J]. J Immunol, 2021, 207(8):2005-2014. DOI:10.4049/jimmunol.2100225.
[14] Kissel T, Hafkenscheid L, Wesemael TJ, et al. IgG anti-citrullinated protein antibody variable domain glycosylation increases before the onset of rheumatoid arthritis and stabilizes thereafter: a cross-sectional study encompassing ~1,500 samples[J]. Arthritis Rheumatol, 2022, 74(7):1147-1158. DOI:10.1002/art.42098.
[15] Bae SH, Hong HK, Lee JY, et al. Plasma antiretinal autoantibody profiling and diagnostic efficacy in patients with autoimmune retinopathy[J]. Am J Ophthalmol, 2023, 245:145-154. DOI:10.1016/j.ajo.2022.07.005.
[16] Zeng HY, Liu Q, Cao K, et al. Serum antiretinal antibodies and cytokine profiling in autoimmune retinopathy and their association with clinical outcomes[J]. Graefes Arch Clin Exp Ophthalmol, 2023, 261(9):2651-2660. DOI:10.1007/s00417-023-06081-6.

ACA、ARA和IgG N-糖基化物与糖尿病视网膜病的关系

Relationships of ACA, ARA, and IgG N-glycosylates with diabetic retinopathy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

[1]	王满华张韬张永刚. 化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变患者的疗效观察 [J]. 国际医药卫生导报, 2024, 30(7): 1136-1141.
[2]	叶剑莉刘慧娜郇菊菊. 思维导图下的个体化护理对糖尿病视网膜病变患者视力水平的影响 [J]. 国际医药卫生导报, 2024, 30(21): 3580-3584.
[3]	王昞苏安乐朱红娜陆慧琴曲晓瑜. 康柏西普注射液对糖尿病视网膜病变患者的治疗效果 [J]. 国际医药卫生导报, 2024, 30(15): 2569-2574.